Replies to post #2863 on Enanta Pharmaceuticals Inc (ENTA)

[DC15]

People can read for themselves, I know, but as a matter of discussion topics between investors I would like to highlight the following from the QA:

While the peds RSV population may be considered more naive than the COVID phase 2 population it is striking that the answers from Enanta indicate that in the RSV peds study virology readouts are key vs symptoms. In the COVID phase 2 symptom measures were the big deal. I also recognize that perhaps scoring symptoms in a pediatric subject is more complex than in an adult subject, but still there was a reversal of logic.

With regard to communication and audience interpretation I felt that the answers provide more doubt that there will be an RSV phase III trial, the answers did not exude confidence although the introductory statements were quite powerful, but they were also powerful for NASH and COVID.